Deer VII & Co’s Protara Therapeutics TARA Stock Holding History

Deer VII & Co’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-7,878	Closed	-$82K	–	5
2019 Q3	$82K	Hold	7,878	–	–	0.09%	5
2019 Q2	$132K	Hold	7,878	–	–	0.12%	4
2019 Q1	$158K	Hold	7,878	–	–	0.5%	4
2018 Q4	$715K	Hold	7,878	–	–	1.99%	4
2018 Q3	$614K	Hold	7,878	–	–	0.92%	4
2018 Q2	$772K	Hold	7,878	–	–	0.92%	4
2018 Q1	$788K	Hold	7,878	–	–	2.94%	3
2017 Q4	$599K	Hold	7,878	–	–	2.42%	3
2017 Q3	$630K	Hold	7,878	–	–	10.12%	2
2017 Q2	$482K	Hold	7,878	–	–	15.66%	2
2017 Q1	$551K	Hold	7,878	–	–	18.28%	2
2016 Q4	$599K	Hold	7,878	–	–	25.51%	2
2016 Q3	$2.94M	Hold	7,878	–	–	1.61%	3
2016 Q2	$2.53M	Hold	7,878	–	–	1.15%	4
2016 Q1	$2.44M	Hold	7,878	–	–	0.62%	4
2015 Q4	$4.89M	Hold	7,878	–	–	1.12%	4
2015 Q3	$4.38M	Hold	7,878	–	–	4.15%	2
2015 Q2	$5.63M	Hold	7,878	–	–	2.3%	5
2015 Q1	$3.3M	Hold	7,878	–	–	1.35%	5
2014 Q4	$2.95M	Buy	+7,878	New	+$3.18M	0.88%	5

Other funds holding TARA

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deer VII & Co's TARA Position: Q4 2019 in Review

Deer VII & Co sold out of Protara Therapeutics (TARA) in Q4 2019, closing a stake of 7,878 shares — an estimated $82K sold.

Deer VII & Co first reported a position in TARA in Q4 2014 and held it in 20 quarters. The position peaked at $5.63M in Q2 2015. 16 funds tracked by Wall St. Rank hold TARA as of Q4 2019.

Deer VII & Co reported no remaining Protara Therapeutics position as of Q4 2019 after selling out during the quarter.
Deer VII & Co sold 7,878 Protara Therapeutics shares in Q4 2019, an estimated $82K.
Deer VII & Co first reported a position in Protara Therapeutics in Q4 2014 and held it in 20 quarters.
Deer VII & Co's Protara Therapeutics position peaked at $5.63M in Q2 2015.
16 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2019.

Based on Deer VII & Co's 13F filing for Q4 2019, filed 14 Feb 2020.